Recent evidence suggested that ertugliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2), suppresses NAFLD development in patients with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.